دورية أكاديمية
أعرض في EDS

Mitigation of cisplatin-induced peripheral neuropathy by canagliflozin in rats.

التفاصيل البيبلوغرافية
العنوان: Mitigation of cisplatin-induced peripheral neuropathy by canagliflozin in rats.
المؤلفون: Abdelsameea AA; Department of Pharmacology, Faculty of Medicine-Zagazig University, Zagazig, Egypt. Ahmedma_72@yahoo.com., Kabil SL; Department of Pharmacology, Faculty of Medicine-Zagazig University, Zagazig, Egypt.
المصدر: Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2018 Sep; Vol. 391 (9), pp. 945-952. Date of Electronic Publication: 2018 Jun 03.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0326264 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1912 (Electronic) Linking ISSN: 00281298 NLM ISO Abbreviation: Naunyn Schmiedebergs Arch Pharmacol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin, New York, Springer Verlag.
مواضيع طبية MeSH: Anti-Inflammatory Agents/*therapeutic use , Canagliflozin/*therapeutic use , Neurotoxicity Syndromes/*drug therapy , Peripheral Nervous System Diseases/*drug therapy , Protective Agents/*therapeutic use, Animals ; Anti-Inflammatory Agents/pharmacology ; Antineoplastic Agents ; Apoptosis/drug effects ; Canagliflozin/pharmacology ; Caspase 3/blood ; Cisplatin ; Glutathione/blood ; Male ; Malondialdehyde/metabolism ; Neurotoxicity Syndromes/blood ; Peripheral Nervous System Diseases/blood ; Protective Agents/pharmacology ; Rats, Wistar ; Tumor Necrosis Factor-alpha/blood
مستخلص: Peripheral nervous system neurotoxicity is the most problematic complication of cisplatin treatment. In this study, we have addressed the possible neuroprotective effect of canagliflozin on cisplatin-induced peripheral neurotoxicity in rats. Rats were randomly allocated into the following: control (vehicle) group, received hydhroxypropyl methyl cellulose; cisplatin group, injected cisplatin 2 mg/kg intraperitoneal, twice a week for 5 consecutive weeks; canagliflozin-cisplatin of received canagliflozin, 10 mg/kg/day by gavage and cisplatin in the same schedule like cisplatin group. Thermal nociception and rotarod performance were assessed. Malondialdehyde (MDA), reduced glutathione (GSH), tumor necrosis factor-α (TNF-α), and caspase 3 were determined in serum. Hematoxylin and eosin (H&E) and immunohistochemical stained sciatic nerve sections were examined. Cisplatin induced thermal hypoalgesia and decreased rotarod performance as well as GSH serum level while increased MDA, TNF-α, and caspase-3 serum levels with atrophy and fragmentation of the nerve fibers with decreased expression of myelin basic protein. Canagliflozin prevented thermal hypoalgesia and improved rotarod performance with increment in GSH serum level while decreased MDA, TNF-α, and caspase-3 levels as well as prevented fragmentation of the nerve fibers and enhanced myelin basic protein expression in relation to cisplatin group. Canagliflozin attenuates the neurotoxic effect of cisplatin through anti-inflammatory and anti-oxidant actions as well as inhibition of apoptosis.
References: Endocr Pract. 2016 Jun;22(6):753-62. (PMID: 27082665)
Redox Biol. 2014 Jan 18;2:289-95. (PMID: 24494204)
Neurosci Lett. 2002 Apr 5;322(2):103-6. (PMID: 11958854)
Hear Res. 2013 May;299:37-45. (PMID: 23467171)
Exp Neurol. 2003 Jul;182(1):12-20. (PMID: 12821373)
Eur J Cancer. 2008 Jul;44(11):1507-15. (PMID: 18571399)
J Neurooncol. 1999 Jan;41(2):107-16. (PMID: 10222430)
DNA Repair (Amst). 2013 Aug;12(8):685-90. (PMID: 23684797)
J Pharmacol Sci. 2006 Jan;100(1):65-72. (PMID: 16410676)
Coll Antropol. 2008 Jan;32 Suppl 1:93-7. (PMID: 18405065)
Endocrinology. 2008 Feb;149(2):455-60. (PMID: 17962345)
Pharmacotherapy. 2017 Feb;37(2):187-194. (PMID: 27931088)
Neurosci Lett. 2015 Jun 2;596:90-107. (PMID: 25459280)
Mol Cancer Ther. 2009 Jan;8(1):10-6. (PMID: 19139108)
Toxicol Appl Pharmacol. 2013 Feb 1;266(3):356-65. (PMID: 23260366)
Neuroscience. 2012 Feb 17;203:194-206. (PMID: 22200546)
Cancer Treat Rev. 2014 Aug;40(7):872-82. (PMID: 24830939)
Head Neck. 2008 Nov;30(11):1445-56. (PMID: 18642321)
Eur J Pharmacol. 2017 Jan 5;794:37-44. (PMID: 27876617)
Biomed Res Int. 2015;2015:167235. (PMID: 25688351)
Am J Transl Res. 2015 Jun 15;7(6):1032-44. (PMID: 26279748)
PLoS One. 2015 Jan 23;10(1):e0116851. (PMID: 25615826)
Anesth Analg. 2013 Jan;116(1):224-31. (PMID: 23223118)
Adv Biomed Res. 2015 May 11;4:92. (PMID: 26015918)
Neurotherapeutics. 2012 Apr;9(2):262-9. (PMID: 22415319)
Crit Rev Oncol Hematol. 2012 Apr;82(1):51-77. (PMID: 21908200)
Toxicol Ind Health. 2015 Sep;31(9):841-51. (PMID: 23552266)
Pain. 2010 May;149(2):393-405. (PMID: 20378247)
Physiol Rep. 2015 Jul;3(7):null. (PMID: 26169541)
Korean J Pain. 2015 Oct;28(4):236-43. (PMID: 26495078)
Shock. 2004 May;21(5):401-9. (PMID: 15087815)
Neurotoxicology. 2013 Jan;34:205-11. (PMID: 23036615)
J Med Econ. 2014 Jun;17(6):394-407. (PMID: 24673364)
ScientificWorldJournal. 2013 Dec 30;2013:565813. (PMID: 24489506)
Behav Pharmacol. 2014 Dec;25(8):732-40. (PMID: 25325291)
Clin Biochem. 1991 Apr;24(2):113-34. (PMID: 1710177)
Neurosci Lett. 2006 Jan 9;392(1-2):22-6. (PMID: 16236448)
Nat Rev Neurol. 2014 Dec;10(12):694-707. (PMID: 25366108)
Toxicology. 2005 Feb 14;207(2):169-77. (PMID: 15596248)
Oxid Med Cell Longev. 2012;2012:542042. (PMID: 23227274)
J Pineal Res. 2007 Jan;42(1):28-42. (PMID: 17198536)
فهرسة مساهمة: Keywords: Apoptosis; Canagliflozin; Caspase-3; Malondialdehyde; Peripheral neuropathy
المشرفين على المادة: 0 (Anti-Inflammatory Agents)
0 (Antineoplastic Agents)
0 (Protective Agents)
0 (Tumor Necrosis Factor-alpha)
0SAC974Z85 (Canagliflozin)
4Y8F71G49Q (Malondialdehyde)
EC 3.4.22.- (Casp3 protein, rat)
EC 3.4.22.- (Caspase 3)
GAN16C9B8O (Glutathione)
Q20Q21Q62J (Cisplatin)
تواريخ الأحداث: Date Created: 20180605 Date Completed: 20181127 Latest Revision: 20181127
رمز التحديث: 20221213
DOI: 10.1007/s00210-018-1521-5
PMID: 29862426
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-1912
DOI:10.1007/s00210-018-1521-5